Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 181Breast Neoplasms 154Prostatic Neoplasms 144Lung Neoplasms 139Glioblastoma 119Head and Neck Neoplasms 115Squamous Cell Carcinoma of Head and Neck 110Rectal Neoplasms 107Lymphoma 101Esophageal Neoplasms 100Pancreatic Neoplasms 76Esophageal Squamous Cell Carcinoma 71Leukemia 70Neoplasms 67Brain Neoplasms 67Lymphoma, Follicular 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Non-Hodgkin 62Lymphoma, Large B-Cell, Diffuse 58Hodgkin Disease 56Uterine Cervical Neoplasms 53Central Nervous System Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Gliosarcoma 51Sarcoma 50Colorectal Neoplasms 50Neoplasm Metastasis 45Lymphoma, Large-Cell, Immunoblastic 45Glioma 44Burkitt Lymphoma 43

Interventions

fludarabine 2Paclitaxel 2Nivolumab 2Bevacizumab 2rucaparib 1liposomal doxorubicin 1dostarlimab 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Melphalan 1Ipilimumab 1Gemcitabine 1Erlotinib Hydrochloride 1Doxorubicin 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Clear Cell × Radiotherapy × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡